Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need. Its lead product candidate, HyBryte™ (synthetic hypericin) for the treatment of CTCL is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. Having a completed a successful Phase 3 trial, the Company is submitting a new drug application to the US FDA for marketing authorization later this year.
For more video content please head to: https://www.youtube.com/c/SoligenixInc
Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties.
Please refer to the Soligenix most recent Form 10-K and Form 10-Q for additional information about the company and related risks.